SARS-CoV-2 neutralising monoVHH antibody - Immunofusion
Alternative Names: SARS-CoV-2 omicron monoVHH neutralising antibody -ImmunofusionLatest Information Update: 09 Jan 2023
At a glance
- Originator Immunofusion
- Class Antivirals; Immunoglobulin Fc fragments; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 09 Jan 2023 SARS-CoV-2 neutralising monoVHH antibody - Immunofusion is available for licensing as of 09 Jan 2023. https://immunofusion.com/#NEUTRALIZATION_ANTIBODY (Immunofusion pipeline, December 2022)
- 30 Dec 2022 Antiviral data from early research in COVID-2019 infections released by Immunofusion (Immunofusion pipeline, December 2022)
- 26 Dec 2022 Immunofusion files for patent for humanized VHH antibody library based receptor binding domain (RBD) binders prior to December 2022 (Immunofusion pipeline, December 2022)